Orpea SA (0NEX) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Orpea SA €18.62, price €10.06, upside +85.2%, quality 49 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Orpea SA for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range €4.78 – €7,041 · fair‑value band €13.04 – €24.69 · the €10.06 price screens below the €18.62 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Orpea in your weekly email
Every Wednesday you see whether Orpea is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
emeis Société anonyme operates nursing homes, assisted-living facilities, post-acute and rehabilitation hospitals, and psychiatric hospitals.
Show more
emeis Société anonyme operates nursing homes, assisted-living facilities, post-acute and rehabilitation hospitals, and psychiatric hospitals. Its services include concierge, housekeeping, ironing, internet connection, TV, telephone, free shuttles, catering and event organization, access to common areas, logistics support, DIY and gardening assistance, IT support, beauty and relaxation treatments, furniture on rent, fitness and wellness areas, and medical visits. The company's post-acute and rehabilitation hospitals offer services for geriatrics, musculoskeletal, nervous system, cardiovascular, hematology, and oncology conditions, as well as patients in a persistent vegetative state or in a minimally conscious state. Its psychiatric hospitals provide services for the patients with mood disorders, anxiety disorders, obsessive-compulsive disorders, addictions, eating disorders, sleep disorders, personality disorders, schizophrenic disorders, autism spectrum disorders, psychotraumatic disorders, neurodegenerative diseases, Perinatal psychiatry, and burn-out. It operates in France, Belgium, Spain, Italy, Ireland, Switzerland, Austria, Germany, the United Kingdom, the Czech Republic, Poland, the Netherlands, Luxembourg, Portugal, Brazil, Russia, Slovenia, Uruguay, Colombia, Mexico, Chile, Latvia, Croatia, and China. The company was founded in 1989 and is headquartered in Puteaux, France.
Stock analysis
Orpea SA (0NEX) currently trades at €10.06, while our model-based Fair Value estimate is €18.62, implying the stock looks roughly 46.0% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of €123.80 per share, and 8 of the 9 models we run sit above the €10.06 price.
Bear case: the Asset-Based group reads lowest at €5.83, and 1 of the 9 models stay below the price. Evidence for this calculation is low.
Scenario range: €13.04 (bear) to €24.69 (bull), the price of €10.06 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 49/100 (below-average quality), in the Industrials sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Orpea SA reported revenue of €5.2B in FY2023 versus €3.7B in FY2019, a compound +8.6%/yr. Reported net income was €1.4B in FY2023, compounding +55.1%/yr from FY2019.
Key figures
Market cap €2.2B · P/S ratio 0.37 · Net margin 26.1% · Return on equity −19.1% · Return on assets (EBIT) 8.2% · Operating margin 2.4% · Revenue (TTM) €5.9B · Revenue growth (YoY) +4.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 36% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Industrials peers we cover trades at −40% fair-value upside, at 85%, 0NEX screens cheaper than that median.
Fair Value models
Bear €13.04Fair Value €18.62Bull €24.69
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.38/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+11.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.7%
Revenue growth 19 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.6%
’12
’13
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
−7.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year−7.9%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.37.8% vs 23.9%, picking up
Profit margin 2017 to 2022 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.13% → −14%
2023 sits 930% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Health Care Facilities” was too small, so the broader sector is used.)Industrials · 5266 stocks
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Orpea SA Fair Value". https://www.fairvalue-calculator.com/stock/0NEX
Frequently asked questions
Is Orpea SA (0NEX) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of €18.62 versus a price of €10.06, about +85% upside (undervalued).
What is the fair value of 0NEX?
Our model-based fair value for Orpea SA is €18.62 (as of Sep 24, 2026), built from audited fundamentals. The current price: €10.06.
What is the quality score of 0NEX?
Orpea SA has a Quality Score of 49/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Orpea SA (0NEX)?
Our model-based price target is the fair value of €18.62 (as of Sep 24, 2026) from 9 valuation models. Cautious scenario €13.04, optimistic scenario €24.69. It is a calculation from audited fundamentals, not an analyst target.
What is the Orpea SA stock forecast for 2026?
Our models put fair value at €18.62, about +85% upside versus a price of €10.06 (undervalued). Cautious scenario €13.04, optimistic scenario €24.69. The calculation is refreshed regularly with new filings.
What is the revenue of Orpea SA (0NEX)?
Orpea SA reported trailing-twelve-month revenue of about €5.9B (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Orpea SA (0NEX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Orpea SA it is €18.62 per share (as of Sep 24, 2026), against a price of €10.06. It is the blended result of 9 valuation models (cash flow, earnings, asset, dividend).
Is Orpea SA stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 0NEX trades below its calculated fair value: price €10.06, fair value €18.62, a gap of about +85% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0NEX?
No. The price is what the market pays today (€10.06); the fair value is what the company's own numbers justify (€18.62). For Orpea SA the two are €8.57 per share apart. That gap is exactly why we show both numbers side by side.
How much is Orpea SA worth?
The market values Orpea SA at about €2.2B (market capitalisation, as of Sep 24, 2026). Per share that is €10.06; our models calculate a fair value of €18.62 per share.
What do the bullish and bearish scenarios say about 0NEX?
Our models span a range for Orpea SA: cautious scenario €13.04, base €18.62, optimistic €24.69 per share (as of Sep 24, 2026, price €10.06). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Orpea SA (0NEX)?
Balance-sheet figures for Orpea SA (as of Sep 24, 2026): return on equity −19.1%, debt of 3.07 per unit of equity. They feed the Quality Score of 49/100, which measures business quality independently of the share price.
How far is 0NEX from its 52-week high?
Orpea SA trades at €10.06, about 36% below its 52-week high of €15.75 and at the low of €10.06 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of €18.62 is for.
Which stocks are comparable to Orpea SA?
From the same area (Industrials) we also value Contemporary Amperex Technology Co, Delta Electronics (Thailand) Public Company, Larsen & Toubro Limited, Samsung C&T Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Orpea SA stock attractive at the current price?
The data as of Sep 24, 2026: price €10.06, calculated fair value €18.62 (+85%), Quality Score 49/100, from 9 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0NEX calculated?
We run Orpea SA through 9 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €18.62, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Orpea SA currently trades 46 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Orpea SA (0NEX)?
The closing price on Oct 2, 2026 was €10.06. Our model-based fair value is €18.62, about +85% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Orpea SA right now?
The price is below even our cautious bear case (€13.04). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (49/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (€13.04 to €24.69) leaves room in how you read the outcome.
Where does the earnings growth of Orpea SA (0NEX) come from?
Earnings per share at Orpea SA grew +19.2 % a year from 2012 to 2023. Broken into its drivers: revenue per share +9.0 %, EBIT margin +17.3 %, tax rate +4.3 %, residual (interest, one-offs) −10.6 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Orpea SA
How large is the market capitalisation of Orpea SA (0NEX)?
The market capitalisation of Orpea SA is €2.2B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Orpea SA (0NEX)?
The price-to-sales ratio of Orpea SA is 0.37 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Orpea SA (0NEX)?
The net margin of Orpea SA is 26.1% (fiscal year 2023). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Orpea SA (0NEX)?
The return on equity (ROE) of Orpea SA is −19.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Orpea SA (0NEX)?
On an EBIT basis the return on assets of Orpea SA is 8.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Orpea SA (0NEX)?
The operating margin of Orpea SA is 2.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Orpea SA (0NEX)?
Revenue at Orpea SA is growing +4.3% versus a year earlier (3y avg +9.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Orpea SA (0NEX) generate?
The free cash flow of Orpea SA is −€90.2M (fiscal year 2023). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Orpea SA (0NEX) carry?
The net debt of Orpea SA is €8.5B (fiscal year 2023). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Orpea SA in the live analysis
One click puts Orpea SA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
